3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
23
Recurrence
3
Neoplasms, Plasma Cell
2
Lymphoma
2
beta-Thalassemia
1
Thalassemia
1
Sarcoma, Myeloid
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plasmablastic Lymphoma
1
Neoplasms
1
Multi-centric Castleman's Disease
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphadenopathy
1
Leukemia, Myeloid, Acute
1
HIV Infections
1
Anemia, Sickle Cell
1
Interventions
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Specimen Handling
1
Radionuclide Imaging
1
Paclitaxel
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Nuclear Medicine Department, Hospital
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Bortezomib
×
30 days
×
Clear all
No trials found.